<p>The gut microbiome comprises trillions of microorganisms and profoundly influences human health by modulating metabolism, immune responses and neuronal functions. Disruption in gut microbiome composition is implicated in various inflammatory conditions, metabolic disorders and neurodegenerative diseases. However, determining the underlying mechanisms and establishing cause and effect is extremely difficult. Preclinical models offer crucial insights into the role of the gut microbiome in diseases and help identify potential therapeutic interventions. The Human Microbiome Action Consortium initiated a Delphi survey to assess the utility of preclinical models, including animal and cell-based models, in elucidating the causal role of the gut microbiome in these diseases. The Delphi survey aimed to address the complexity of selecting appropriate preclinical models to investigate disease causality and to study host–microbiome interactions effectively. We adopted a structured approach encompassing a literature review, expert workshops and the Delphi questionnaire to gather insights from a diverse range of stakeholders. Experts were requested to evaluate the strengths, limitations, and suitability of these models in addressing the causal relationship between the gut microbiome and disease pathogenesis. The resulting consensus statements and recommendations provide valuable insights for selecting preclinical models in future studies of gut microbiome-related diseases.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

A Consensus Statement on establishing causality, therapeutic applications and the use of preclinical models in microbiome research

  • Amira Metwaly,
  • Aicha Kriaa,
  • Zahra Hassani,
  • Federica Carraturo,
  • Celine Druart,
  • Jonel Trebicka,
  • Yolanda Godoy,
  • Robert Schierwagen,
  • Peer Bork,
  • Anandhi Iyappan,
  • Nassos Typas,
  • Diënty Hendrina Maria Johanna Hazenbrink,
  • Hub Zwart,
  • Laurence Zitvogel,
  • Lisa Derosa,
  • Carolina Alves Costa Silva,
  • Moez Rhimi,
  • Patrick Veiga,
  • Nicolas Pons,
  • Pierre-Louis Prost,
  • Fay Betsou,
  • Magali Cordaillat-Simmons,
  • Julie Rodriguez,
  • Alexander Jarde,
  • Isabelle Boutron,
  • Philippe Ravaud,
  • Aleksander Krag,
  • Mads Israelsen,
  • Ida Falk Villesen,
  • Paul Ross,
  • Paul O’Toole,
  • Aonghus Lavelle,
  • Marcus Claesson,
  • Raphaela Joos,
  • Colin Hill,
  • Andrey Shkoporov,
  • Saba Loftus,
  • Katy Boucher,
  • Manimozhayan Arumugam,
  • Arjun Sarathi,
  • Vitalina Morozova,
  • Nicola Segata,
  • Francesco Asnicar,
  • Federica Pinto,
  • Kaline Arnauts,
  • Paul Wilmes,
  • Jens Walter,
  • Stephan Rosshart,
  • Mahesh S. Desai,
  • Joel Dore,
  • Alessio Fasano,
  • Hervé M. Blottiere,
  • Emmanuelle Maguin,
  • Dirk Haller

摘要

The gut microbiome comprises trillions of microorganisms and profoundly influences human health by modulating metabolism, immune responses and neuronal functions. Disruption in gut microbiome composition is implicated in various inflammatory conditions, metabolic disorders and neurodegenerative diseases. However, determining the underlying mechanisms and establishing cause and effect is extremely difficult. Preclinical models offer crucial insights into the role of the gut microbiome in diseases and help identify potential therapeutic interventions. The Human Microbiome Action Consortium initiated a Delphi survey to assess the utility of preclinical models, including animal and cell-based models, in elucidating the causal role of the gut microbiome in these diseases. The Delphi survey aimed to address the complexity of selecting appropriate preclinical models to investigate disease causality and to study host–microbiome interactions effectively. We adopted a structured approach encompassing a literature review, expert workshops and the Delphi questionnaire to gather insights from a diverse range of stakeholders. Experts were requested to evaluate the strengths, limitations, and suitability of these models in addressing the causal relationship between the gut microbiome and disease pathogenesis. The resulting consensus statements and recommendations provide valuable insights for selecting preclinical models in future studies of gut microbiome-related diseases.